Reverse Transcriptase Inhibitors in HIV/AIDS Therapy

  • Vassil St.Georgiev
  • Gail Skowron
  • Richard Ogden
  • Joep M. A. Lange

Part of the Infectious Disease book series (ID)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Monica Carten, Harold Kessler
    Pages 33-76
  3. Gail Skowron, Sapna Chowdhry, Michael R. Stevens
    Pages 77-132
  4. Gail Skowron, Jeffrey Bratberg, Rudi Pauwels
    Pages 133-156
  5. Craig J Hoesley
    Pages 157-178
  6. Patrick Hoggard, Stephen Kewn, Saye Khoo, David Back
    Pages 209-236
  7. Grace McComsey
    Pages 281-302
  8. David Asmuth, Richard Pollard
    Pages 303-344
  9. Graeme J. Moyle, Brian Conway
    Pages 345-373
  10. Brian Conway
    Pages 375-400
  11. F. Ramzi Asfour, Richard Haubrich
    Pages 401-424
  12. Susan Cu-Uvin, Arlene Bardeguez, Carla Chibwesha
    Pages 425-470
  13. Allan Ronald, Elly Katabira, Merle Sande
    Pages 499-513
  14. Back Matter
    Pages 517-527

About this book


Despite significant pharmacological advances, the backbone of the most highly active antiretroviral therapy regimens for controlling HIV/AIDS is still a combination of reverse transcriptase inhibitors (RTIs) first discovered in the late 1980s. In Reverse Transcriptase Inhibitors in HIV/AIDS Therapy, leading experts in AIDS/HIV drug discovery and development review all aspects of RTIs (nucleosides, nucleotides, and non-nucleosides), including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment in general, and on vertical transmission in the developing world. Highlights include a thorough discussion of side effects, resistance, and treatment in the third world.
Comprehensive and up-to-date, Reverse Transcriptase Inhibitors in HIIV/AIDS Therapy offers a magisterial survey of the discovery, clinical development, current use, and future possibilities of all drugs that treat HIV/AIDS by inhibiting the viral reverse transcriptase.


AIDS HIV HIV/AIDS drug drug discovery drug resistance kinetics pharmacokinetics pharmacology prevention resistance toxicity

Editors and affiliations

  • Vassil St.Georgiev
    • 1
  • Gail Skowron
    • 2
    • 3
  • Richard Ogden
    • 4
  • Joep M. A. Lange
    • 5
  1. 1.National Institute of Allergy and Infectious Diseases National Institutes of HealthUSA
  2. 2.Division of Infectious DiseasesRoger Williams Medical CenterProvidence
  3. 3.Boston University School of MedicineBoston
  4. 4.Pfizer Inc.San Diego
  5. 5.Center for Poverty-Related Communicable Diseases Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Bibliographic information